#ACR25 Beyond blinatumomab, A-319, CD3xCD19 BiTE in 12 patients with #SLE in China reported dose-dependent depth of B-Cell depletion but not efficacy or safety. One withdrew due to AE. No CRS/ICANS. Be interested to see results in larger trials & longer follow-up @RheumNow https://t.co/e5RuZlFI6i

• https://x.com/Yuz6Yusof/status/1982504797036216616/photo/1
• https://x.com/Yuz6Yusof/status/1982504797036216616/photo/1

After propensity matching, this retrospective cohort study showed that #lupus nephritis patients on GLP-1 agonists had ⬇️ CKD progression, mortality & AMI risk vs. LN pts on SGLT2is. Interesting data but what could explain it? Further studies are needed #ACR25 @RheumNow Abs0841 https://t.co/FtsGbMDcCv

• https://x.com/RHEUMarampa/status/1982499968767185041/photo/1

#ACR25 Abstr#645. Dapirolizumab, anti-CD40L-i met primary endpoint, BICLA in Phase 3 RCT non-renal SLE. Key secondary endpoints showed higher rates of & time in LLDAS and remission in DAP vs PBO. Meaningful targets re: damage accrual & better longterm outcomes @RheumNow https://t.co/IxesXhi34R

• https://x.com/Yuz6Yusof/status/1982499943219957924/photo/1
• https://x.com/Yuz6Yusof/status/1982499943219957924/photo/1

#ACR25 Abstr#641 Phase 1/2 CASTLE Basket Trial fully recruited N=24 (10 SLE, 9 SSc, 5 IIM). Short-term data of autologous CD19-CAR T Zorpocabtagene-autoleucel/MB19.1: - 22/24 high degree efficacy - no relapse - no high grade CRS/ICANS *Need larger Phase prior approval @RheumNow https://t.co/sp1nieeCvl

• https://x.com/Yuz6Yusof/status/1982496709860344006/photo/1

Abstract 0806 Compared to belimumab, Anifrolumab associated with: ↑ infection risk b (HR 1.40, 95% CI 1.05–1.88) ↑ herpes zoster (HR 3.94) & COVID-19 (HR 1.66) No diff in mortality or hospital use 📈 3-yr infection: 38.3% vs 21.3% @RheumNow #ACR25

Real world effectiveness of voclosporin for SLE Reduction in UPCR from 2.1 at b/l to 0.9 at 6 months, no improvement in eGFR; as expected based on trials Wonder about market share of BEL vs voclo vs ANI - anyone seen pubs on this? #ACR25 @RheumNow Abstr#0661 https://t.co/l7i7IWhLSe

• https://x.com/EBRheum/status/1982478074810662970/photo/1

Statins and SLE: To add or not to add? 💊 Abstract #0599: In an emulated target trial of patients with SLE, statin users vs non-users had significantly⬇️ risk of all-cause death in both ITT & per-protocol analyses. - No significant differences in MACE or ESKD. @RheumNow #ACR25

SLE & arthritis: Is there a difference? Abstract #0629: - Non-deforming (ND): 73% | Jaccoud’s: 19% | Rhupus: 8% - Vs ND, Rhupus had lower odds of type I IFN signature - Time to deformities: Jaccoud's ~2 yrs vs Rhupus ~5 yrs - RNP+ predictive of Jaccoud’s @RheumNow #ACR25

Managing lupus is complex. How do we ensure quality care? Abstract #0218 convened 8 focus groups: ✅ Support for patient navigators ⚠️ Barriers: low resources, staff turnover 💻 Solution: EHR outreach workflow to flag missed visits & labs @RheumNow #ACR25 https://t.co/BWaIMMEPit

• https://x.com/AkhilSoodMD/status/1982472035658826210/photo/1

Abstract #0607: The age at diagnosis of SLE is rising in US based cohort📈 Those diagnosed ≥30 yrs were: ⬆️ More likely to have oral ulcers, hematologic features, +ANA ⬇️ Less likely to have malar rash or proteinuria @RheumNow #ACR25 https://t.co/pMPVLg1xTZ

• https://x.com/AkhilSoodMD/status/1982472034639814707/photo/1

Abstract 0196: Too many referrals, too few slots? A hybrid RN + MD referral cut wait times for patients with SLE by 26% Median time to appointment 69 days --> 51 days Next steps: streamline high-risk triage, reduce manual chart review @RheumNow #ACR25

Dr. Werth on the #SLE guidelines on tx of cutaneous LE: 🔅All patients should be on hydroxychloroquine unless with CI. ☝️Important! For SLE pts presenting with new-onset rashes, review/ask about medications; consider drug-induced SCLE. #ACR25 @RheumNow https://t.co/ok5jAi7uO0

• https://x.com/RHEUMarampa/status/1982466797971386674/photo/1
• https://x.com/RHEUMarampa/status/1982466797971386674/photo/1

#ACR25 In a rush and wondering which abstract to look out for pertaining to new update on Biologics in #SLE #lupus? Please find my article on conference preview @RheumNow https://t.co/usIXPsj5bm https://t.co/4wmWvDyv83

• SLE Conference Preview: progress in biologics | RheumNow
• https://x.com/Yuz6Yusof/status/1982466449328189855/photo/1

#ACR25 Abstr#0772. Should we be worried of #SLE patients with low uPCR 0.25-0.49? Kidney biopsy in N=28 + poor prognostic (Non-White, active serology or active sediment) - 71% had LN (No class IV or Mixed) - 46% actionable LN Cost-effectiveness data needed. #ACRBest @RheumNow https://t.co/Bt3fuA3aJh

• https://x.com/Yuz6Yusof/status/1982463761941254262/photo/1
• https://x.com/Yuz6Yusof/status/1982463761941254262/photo/1

Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ilKWG8CQbe

• https://x.com/NaziburM/status/1982463066194276479/photo/1